NovusTex, Corp.

NovusTex is a Delaware C-Corp building human-relevant bioprinted tissue platforms to make drug development more predictive, less wasteful, and closer to real human biology.

Our beachhead product is a bioprinted human nasal cartilage platform designed for intranasal drug development, toxicity testing, formulation evaluation, and translational assay design. Intranasal therapeutics are gaining momentum across CNS, emergency medicine, pain, seizure rescue, vaccines, and biologics, yet companies still lack reliable human-relevant models to evaluate how formulations interact with nasal tissue before entering costly preclinical and clinical workflows.

NovusTex addresses this gap by developing standardized, reproducible tissue constructs that can help biotech, pharmaceutical, biomaterials, and bioink companies test earlier, fail smarter, and generate stronger translational evidence. By starting with nasal cartilage, a structurally important and relatively low-vascular-demand tissue, NovusTex has a focused technical entry point with expansion potential into broader mucosal, cartilage, and patient-specific craniofacial applications.

The company sits at the intersection of bioprinting, regenerative medicine, FDA’s New Approach Methodologies initiative, and translational drug development. Its long-term vision is to become a human-tissue infrastructure company: providing validated tissue systems that reduce reliance on imperfect animal models, improve preclinical decision-making, and accelerate the path from formulation to patient impact.

NovusTex is not building another research tool. It is building the human tissue layer drug development has been missing.